Takeda Archives - Page 6 of 15 -

2019: the year of the pharma mega-merger

Richard Staines AbbVie, Allergan, Biogen, BMS, Celgene, M&A, Merck & Co, Novartis, Pfizer, Roche, Shire, Takeda 0 Comment

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year

2019: the year of the pharma mega-merger

https://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/

News/ News/ Oncology

Takeda sets sights on first-line lung cancer market with new Alunbrig data

Phil Taylor Alecensa, Alunbrig, Non-small cell lung cancer, Novartis, Oncology, Pfizer, Roche, Takeda, Xalkori 0 Comment

Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a

Takeda sets sights on first-line lung cancer market with new Alunbrig data

https://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/

Dengue, zika and chikungunya fever mosquito (aedes aegypti) on human skin

News/ News/ R&D

Experts concerned over mixed results from Takeda’s dengue vaccine

Richard Staines dengue, infectious diseases, Sanofi, Takeda, vaccine 0 Comment

Takeda’s dengue vaccine has met its target of protection against the disease in children – but there are

Experts concerned over mixed results from Takeda’s dengue vaccine

https://pharmaphorum.com/news/experts-concerned-over-mixed-results-from-takedas-dengue-vaccine/

News/ News/ Sales and Marketing

Takeda nets $660m from product selloff to Germany’s Stada

Phil Taylor emerging markets, generic, OTC, Russia, Stada, Takeda 0 Comment

Takeda has divested another block of products it views as lying outside its main focus, selling various drugs

Takeda nets $660m from product selloff to Germany’s Stada

https://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/

News/ News/ R&D

Takeda buys coeliac drug licence from COUR Pharmaceuticals

Richard Staines coeliac disease, gastroenterology, Takeda 0 Comment

Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced

Takeda buys coeliac drug licence from COUR Pharmaceuticals

https://pharmaphorum.com/news/takeda-buys-coeliac-drug-licence-from-cour-pharmaceuticals/

News

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

Richard Staines Acino, M&A, Takeda 0 Comment

Takeda is to sell off a portfolio of over-the-counter and prescription drugs in the Near East, Middle East,

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

https://pharmaphorum.com/news/takeda-to-sell-otc-drugs-in-middle-east-and-africa-for-200m/

News/ News/ Oncology

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

Richard Staines AstraZeneca, cancer, ImaginAb, immunotherapy, Pfizer, Takeda 0 Comment

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that

ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

https://pharmaphorum.com/news/imaginab-joins-with-az-pfizer-and-takeda-to-develop-tumour-imaging-tech/

News/ Top stories

Takeda breaks into top 20 largest pharmas with Shire merger

Richard Staines M&A, Takeda 0 Comment

Takeda broke into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger

Takeda breaks into top 20 largest pharmas with Shire merger

https://pharmaphorum.com/news/takeda-breaks-into-top-20-largest-pharmas-with-shire-merger/

News/ News/ Sales and Marketing

Takeda eyes emerging markets asset sale to trim its debt; report

Phil Taylor Financial, M&A, Shire, Takeda 0 Comment

Takeda is said to be considering the sale of assets in emerging markets and western Europe to pay

Takeda eyes emerging markets asset sale to trim its debt; report

https://pharmaphorum.com/news/takeda-eyes-emerging-markets-asset-sale-to-trim-its-debt-report/

Trending

Takeda

Login